Similar articles

• Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

  Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ. Bartlett JM, et al. Lancet Oncol. 2010 Mar;11(3):266-74. doi: 10.1016/S1470-2045(10)70006-1. Epub 2010 Jan 13. Lancet Oncol. 2010. PMID: 20079691
• Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.

  Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D. Tibau A, et al. Neoplasia. 2014 Oct 23;16(10):861-7. doi: 10.1016/j.neo.2014.08.012. eCollection 2014 Oct. Neoplasia. 2014. PMID: 25379022 Free PMC article. Clinical Trial.
• Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.

  Slamon DJ, Press MF. Slamon DJ, et al. J Natl Cancer Inst. 2009 May 6;101(9):615-8. doi: 10.1093/jnci/djp092. Epub 2009 Apr 28. J Natl Cancer Inst. 2009. PMID: 19401550 No abstract available.
• [Topo II alpha in breast cancer: an update].

  Wei J, Liu FF, Fu L. Wei J, et al. Zhonghua Bing Li Xue Za Zhi. 2008 Feb;37(2):132-5. Zhonghua Bing Li Xue Za Zhi. 2008. PMID: 18681328 Review. Chinese. No abstract available.
• Chemotherapy regimens in early breast cancer: major controversies and future outlook.

  Joerger M, Thürlimann B. Joerger M, et al. Expert Rev Anticancer Ther. 2013 Feb;13(2):165-78. doi: 10.1586/era.12.172. Expert Rev Anticancer Ther. 2013. PMID: 23406558 Review.